Long-term (18-month) efficacy of atorvastatin therapy in type 2 diabetics at cardiovascular risk

Nutrition, Metabolism and Cardiovascular Diseases

Volumn 12, Issue 1, 2002, Pages 29-35

  Velussi, M ^a  

^a Diabetic Clinic   (Italy)

Author keywords

Atorvastatin; Dyslipidemia; Type 2 diabetes

Indexed keywords

ATORVASTATIN; HEPTANOIC ACID DERIVATIVE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PYRROLE DERIVATIVE; TRIACYLGLYCEROL;

ARTICLE; BLOOD; CARDIOVASCULAR DISEASE; COHORT ANALYSIS; DOSE RESPONSE; DRUG EFFECT; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; LONGITUDINAL STUDY; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; RISK FACTOR; TREATMENT OUTCOME;

ANTICHOLESTEREMIC AGENTS; CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; CHOLESTEROL, LDL; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEPTANOIC ACIDS; HUMANS; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIAS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PYRROLES; RISK FACTORS; TREATMENT OUTCOME; TRIGLYCERIDES;

EID: 0036463514     PISSN: 09394753     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Coutinho M, Gerstein HC, Wang Y, Yusuf S (1999) The relationship between glucose and incident cardiovascular events: a metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care 22: 223-240
2. Laakso M (1999) Hyperglycemia and cardiovascular disease in type 2 diabetes. Diabetes 48: 937-942
3. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR (2000) Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 321: 405-412
4. Stamler J, Vaccaro O, Neaton JD, Wentworth D (1993) Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 16: 434-444
5. Malmberg K, Ryden I (1988) Myocardial infarction in patients with diabetes mellitus. Eur Heart J 9: 256-264
6. Fontbonne A, Escwege E, Cambien F, Richard JL, Ducimetiere P, Thibuylt N (1989) Hypertriglyceridaemia as a risk factor of coronary heart disease mortality in subjects with impaired glucose tolerance or diabetes. Results from the 11-year follow-up of the Paris Prospective Study. Diabetologia 32: 300-304
7. Lehto S, Ronnemaa T, Haffner SM, Pyorala K, Kallio V, Laakso M (1997) Dyslipidaemia and hyperglycemia predict coronary heart disease events in middle-aged patients with NIDDM. Diabetes 48: 1354-1359
8. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) (1994) Lancet 344: 1383-1389
9. Pyorala K, Pedersen TR, Kjekshus J, Faergeman O, Olsson AG, Thorgeirsson G (1997) Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 20: 614-620
10. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JM, Wun CC, Davis BR, Braunwald E (1996) The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial Investigators. N Engl J Med 335: 1001-1009
11. Velussi M, Cernigoi AM, Tortul C, Merni M (1999) Atorvastatin for the management of Type 2 diabetic patients with dyslipidaemia. A mid-term (9 months) treatment experience. Diabetes Nutr Metab 12: 407-412
12. Bakker-Arkema RG, Nawrocki JW, Black DM (2000) Safety profile of atorvastatin-treated patients with low LDL-cholesterol levels. Atherosclerosis 149: 123-129
13. McVey D, Patel H, Eminton Z, Maton S (1999) An assessment of the efficacy of atorvastatin in treating patients with dyslipidaemia to target LDL-cholesterol goals: the atorvastatin matrix study. Int J Clin Pract 53: 509-513
14. Noseda G, Darioli R, Keller U, Mordasini R, Shokry A, Schaffhauser R, Riesen W (2000) Evaluating the efficacy and tolerance of atorvastatin in hyperlipidemia in general practice (SWITCH Study) Schweiz Med Wochenschr 130: 889-895
15. Raal FJ, Pappu AS, Illingworth DR, Pilcher GJ, Marais AD, Firth JC, Kotze MJ, Heinonen TM, Black DM (2000) Inhibition of cholesterol synthesis by atorvastatin in homozigous familial hypercholesterolemia. Atherosclerosis 150: 421-428
16. Frost RJ, Otto C, Geiss HC, Schwandt P, Parhofer KG (2001) Effects of atorvastatin versus fenofibrate on lipoprotein profiles, low density lipoprotein subfraction distribution, and hemorheologic parameters in type 2 diabetes mellitus with mixed hyperlipoproteinemia. Am J Cardiol 87: 44-48
17. Insull W, Kafonek S, Doldner D, Zieve F (2001) Comparison of efficacy and safety of atorvastatin (10 mg) with simvastatin (10 mg) at six weeks. Am J Cardiol 87: 554-559
18. Gentile S, Turco S, Guarino G, Sasso CF, Amodio M, Magliano P, Salvatore T, Corigliano G, Agrusta M, De Simone G, Gaeta I, Oliviero B, Torella R (2000) Comparative efficacy study of atorvastatin vs simvastatin, pravastatin, lovastatin and placebo in type 2 diabetic patients with hypercholesterolaemia. Diabetes Obes Metab 2: 355-362
19. de Man FH, Weverling-Rijnsburger AW, van der Laarse A, Smelt AH, Jukema JW, Blauw GJ (2000) Not acute but chronic hypertriglyceridemia is associated with impaired endothelium-dependent vasodilation: reversal after lipid-lowering therapy by atorvastatin. Arterioscler Thromb Vasc Biol 20: 744-750
20. Wierzbicki AS, Lumb PJ, Semra YK, Crook MA (1997) Effect of atorvastatin on plasma fibrinogen. Lancet 351: 569-570
21. Frost RJ, Otto C, Geiss HC, Schwandt P, Parhofer KG (2001) Effects of atorvastatin on lipoprotein profiles, low-density lipoprotein subfraction distribution and hemorheologic parameters in type 2 diabetes mellitus with mixed hyperlipoproteinemia. Am J Cardiol 87: 44-48